{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:10:23Z","timestamp":1781928623255,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.biopha.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T01:02:32Z","timestamp":1537923752000},"page":"893-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives"],"prefix":"10.1016","volume":"108","author":[{"given":"Mohammad-Ali","family":"Sobhanifar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-5455","authenticated-orcid":false,"given":"Baratali","family":"Mashkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saadatmandzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Sadeghnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hadi","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2018.09.001_bib0010","first-page":"351","article-title":"Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues","volume":"58","author":"DeLapeyri\u00e8re","year":"1995","journal-title":"Differentiation"},{"issue":"9","key":"10.1016\/j.biopha.2018.09.001_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.biopha.2018.09.001_bib0020","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3 A cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.biopha.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1158\/0008-5472.CAN-06-4807","article-title":"Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?","volume":"67","author":"Rassool","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.001_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2008.02.006","article-title":"FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia","volume":"183","author":"Pinheiro","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"issue":"24","key":"10.1016\/j.biopha.2018.09.001_bib0035","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.biopha.2018.09.001_bib0040","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.001_bib0055","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.001_bib0060","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood."},{"issue":"5682","key":"10.1016\/j.biopha.2018.09.001_bib0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.biopha.2018.09.001_bib0070","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.biopha.2018.09.001_bib0075","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.biopha.2018.09.001_bib0080","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","article-title":"A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response","volume":"113","author":"Pratz","year":"2009","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.biopha.2018.09.001_bib0085","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1182\/blood-2008-05-156422","article-title":"Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.biopha.2018.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/jm0100335","article-title":"Synthesis and antibacterial evaluation of certain quinolone derivatives","volume":"44","author":"Chen","year":"2001","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0014-827X(98)00037-8","article-title":"Synthesis and pharmacological properties of some quinoline derivatives","volume":"53","author":"Kalluraya","year":"1998","journal-title":"Il Farm."},{"key":"10.1016\/j.biopha.2018.09.001_bib0100","first-page":"245","volume":"vol. 5","author":"Balasubramanian","year":"1996"},{"issue":"18","key":"10.1016\/j.biopha.2018.09.001_bib0105","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0960-894X(00)00378-4","article-title":"A novel inhibitor of human telomerase derived from 10H-indolo [3, 2-b] quinoline","volume":"10","author":"Caprio","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2018.09.001_bib0110","series-title":"Heterocyclic Compounds","author":"Elderfield","year":"1950"},{"issue":"10","key":"10.1016\/j.biopha.2018.09.001_bib0115","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2174\/092986711795328382","article-title":"Quinoline as a privileged scaffold in cancer drug discovery","volume":"18","author":"Solomon","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00894-009-0501-6","article-title":"Quinoline alkaloids as intercalative topoisomerase inhibitors","volume":"15","author":"Byler","year":"2009","journal-title":"J. Mol. Model."},{"issue":"9","key":"10.1016\/j.biopha.2018.09.001_bib0125","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1021\/jm00061a005","article-title":"Synthesis and cytotoxicity of 1, 6, 7, 8-substituted 2-(4\u2019-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin","volume":"36","author":"Kuo","year":"1993","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.001_bib0130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1006\/bbrc.1999.0245","article-title":"Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells","volume":"255","author":"Nakamura","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.001_bib0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejphar.2009.06.063","article-title":"Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies","volume":"625","author":"Solomon","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/jm9707479","article-title":"Antitumor agents. 181.\u2020 Synthesis and biological evaluation of 6, 7, 2 \u2018, 3 \u2018, 4 \u2018-substituted-1, 2, 3, 4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents","volume":"41","author":"Xia","year":"1998","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.001_bib0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/jm020241c","volume":"46","author":"Wissner","year":"2003","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.biopha.2018.09.001_bib0150","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.bmcl.2003.09.028","article-title":"Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGF\u03b2 receptor kinase (T\u03b2RI)","volume":"13","author":"Singh","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2018.09.001_bib0155","unstructured":"Myers MR, Spada AP, Persons PE, Maguire MP. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and\/or p56lck tyrosine kinases. Google Patents; 2003."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.001_bib0160","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/jm000420z","article-title":"Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles","volume":"44","author":"Boschelli","year":"2001","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.biopha.2018.09.001_bib0165","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1021\/jm061031t","article-title":"Synthesis and Src kinase inhibitory activity of a series of 4-[(2, 4-dichloro-5-methoxyphenyl) amino]-7-furyl-3-quinolinecarbonitriles","volume":"49","author":"Boschelli","year":"2006","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10495-008-0209-6","article-title":"A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death","volume":"13","author":"Hurren","year":"2008","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.biopha.2018.09.001_bib0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mnfr.200700326","article-title":"Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways","volume":"52","author":"Ramos","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.001_bib0180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0306-3623(98)00220-1","article-title":"Flavonoids and the inhibition of PKC and PI 3-kinase","volume":"32","author":"Gamet-Payrastre","year":"1999","journal-title":"Gen. Pharmacol. Vasc. Syst."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist. Updates"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.001_bib0190","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.freeradbiomed.2004.01.001","article-title":"Flavonoids: antioxidants or signalling molecules?","volume":"36","author":"Williams","year":"2004","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0195","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","article-title":"PI3K-Akt pathway: its functions and alterations in human cancer","volume":"9","author":"Osaki","year":"2004","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.001_bib0200","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.001_bib0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase\u2013AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.001_bib0210","first-page":"321","article-title":"Synthesis and docking analysis of new heterocyclic system N1, N4-bis (2-chloroquinolin-3-yl) methylene) benzene-1, 4-diamine as potential human AKT1 inhibitor","volume":"15","author":"Ghanei","year":"2016","journal-title":"Iran. J. Pharm. Res.: IJPR"},{"issue":"4","key":"10.1016\/j.biopha.2018.09.001_bib0215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.biopha.2018.09.001_bib0220","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2016.02.048","article-title":"FMS-like tyrosine kinase 3 (FLT3) inhibitors: molecular docking and experimental studies","volume":"776","author":"Mashkani","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"4-6","key":"10.1016\/j.biopha.2018.09.001_bib0225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3923\/biotech.2017.174.181","article-title":"Expression of mouse granulocyte-macrophage colony stimulating factor (GM-CSF) in Pichia pastoris","volume":"16","author":"Madadi","year":"2017","journal-title":"Biotechnology"},{"issue":"4","key":"10.1016\/j.biopha.2018.09.001_bib0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1134\/S000368381704007X","article-title":"Overexpression of functional human FLT3 ligand in Pichia pastoris","volume":"53","author":"Karimi","year":"2017","journal-title":"Appl. Biochem. Microbiol."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.001_bib0235","first-page":"261","article-title":"Study of cytotoxic effects of saffron in MCF-7 cells","volume":"4","author":"Mousavi","year":"2008","journal-title":"Iran. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.001_bib0240","first-page":"410","article-title":"Ctotoxic and apoptogenic effects of Perovskia abrotanoides flower extract on MCF-7 and HeLa cell lines","volume":"6","author":"Geryani","year":"2016","journal-title":"Avicenna J. Phytomed."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.001_bib0245","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"291","key":"10.1016\/j.biopha.2018.09.001_bib0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5731","article-title":"Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia","volume":"7","author":"Lim","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2018.09.001_bib0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2024.117618","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217363813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217363813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:32:13Z","timestamp":1777271533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217363813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":51,"alternative-id":["S0753332217363813"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.09.001","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}